SCHEMBL26527738

SCHEMBL26527738

CN(CC(=O)N1Cc2ccccc2C1)Cc1nc2c(cnn2C)c(=O)n1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.39
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NLRP3 Q96P20 1/20 0.37
ALDH1A1 P00352 9/20 0.37
ALDH1A3 P47895 4/20 0.37
ATAD2 Q6PL18 1/20 0.36
ALDH1A2 O94788 3/20 0.36
ACKR3 P25106 1/20 0.35
USP7 Q93009 2/20 0.35
F7 P08709 1/20 0.34
F3 P13726 1/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26529976 0.86 KMT2A (0.42) KDM4EKMT2AALDH1A1ALDH1A3ATAD2
SCHEMBL23723707 0.81 TNKS (0.42) KDM4EMEN1KMT2ANLRP3ALDH1A1
SCHEMBL30132053 0.81 TNKS (0.42) KDM4EMEN1KMT2ANLRP3ALDH1A1
SCHEMBL23749881 0.67 TNKS (0.47) KMT2AALDH1A1HPGD
SCHEMBL30132060 0.66 KMT2A (0.60) KDM4EMEN1KMT2AALDH1A1HSD17B10
SCHEMBL23723704 0.65 KMT2A (0.42) KDM4EMEN1KMT2AALDH1A1HSD17B10
SCHEMBL24120936 0.63 ALDH1A1 (0.40) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL21271734 0.63 ALDH1A1 (0.62) ALDH1A1ALDH1A3ALDH1A2
SCHEMBL26096345 0.62 KMT2A (0.47) GAAKDM4EMEN1KMT2AALDH1A1
SCHEMBL26097137 0.62 KMT2A (0.47) KDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 GAA 4/4885KDM4E 3566/4885MEN1 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.